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The development of potential therapeutic and
prophylactic vaccines for human papillomavirus
(HPV) infection is a very exciting area of HPV
research. There are a number of features of HPV
biology that makes the development of a vaccine
particularly dif®cult, although there are several
examples of vaccines that have had spectacular suc-
cess in the prevention of other viral diseases. Our
poor understanding of the immune response to HPV
infection is the ®rst problem. We do not understand
the mechanism by which spontaneous clearing of
warts is generated and therefore cannot particularly
target this pathway in the development of a vaccine.
Furthermore, there is no in vitro culture system nor
an animal model for HPV. Another problem is that
there is no ready source of live virus that might be
exploited for a live attenuated viral vaccine, such as
was used with poliovirus. Although most other vir-
uses spend a portion of their life cycle in the sys-
temic circulation where they are vulnerable to
neutralizing antibodies, HPV remain exclusively in
the epithelium and thus antibodies must transverse
the basement membrane and reach the other layers
of the skin or mucosa to be effective in preventing
infection. Signi®cant progress is being made in the
development of potential vaccine candidates despite
these and other confounding factors. Key words: anti-
bodies/virus-like particles. Journal of Investigative
Dermatology Symposium Proceedings 6:238±243, 2001
MICROBIOLOGY
Human papillomaviruses (HPV) are small, nonenveloped
icosahedral viruses with a diameter of about 55 nm containing
8±10 genes on circular double-stranded DNA. Three functional
regions are contained in the HPV genome. Transcription
enhancer and promoter elements are found in the long-control
region. Open reading frames are found in the early region, the
products of which control viral replication, transcription, and
cellular transformation, and encode for E6 and E7 oncoproteins.
Two capsid structural proteins (the L1 major and the L2 minor)
are encoded in the late region. There is immunogenic, and thus
vaccine potential, in each of these proteins. Humans can be
infected by over 80 types of papillomavirus. High-risk HPV
types include HPV 16, 18, 31, 35, 45, 51, 52, 56, 58 and 66 as
they may cause squamous cell carcinoma and premalignant
cervical lesions (Lorinez et al, 1992; Kiviat and Koutsky, 1993;
Schiffman et al, 1993; Bosch et al, 1995). Over 90% of cervical
carcinomas (Gissmann et al, 1983; Brown et al, 1993;
Walboomers et al, 1994) are associated with HPV types 16
and 18. At least 80% of anal carcinomas contain HPV DNA,
type 16 being the most common (Zaki et al, 1992). Over 90%
of condyloma acuminata are caused by low-risk HPV types 6
and 11.
IMMUNOLOGY/IMMUNOBIOLOGY OF INFECTION
Strati®ed squamous epithelial cells are infected by HPV. El
helicase and E2 transactivator are responsible for viral DNA
replication and RNA transcription. The viral capsid proteins (L1
and L2) are produced in the upper layers of differentiating
epithelium. Human papillomavirus-containing epithelial cells are
shed from the surface of the skin. A relatively large area of
skin, probably in the order of 2±3 mm2 (Steele and Gallimore,
1990), can be infected by the progeny of a single HPV-infected
stem cell. As there is no cell lysis, there is no release of viral
proteins and poor antigen presentation to the immune system.
Antibody to both capsid proteins of the virus are produced,
however, during the course of HPV infection (Christensen et al,
1992). After an average of 6 mo following infection this
acquired immunity occurs and may be protective against
reinfection, but is not likely to be therapeutic.
The progression of HPV infection to clinical disease appears
to be regulated by host immune responses to HPV. Both
humoral and cell-mediated immune responses are elicited by
HPV. A crucial role in modulating the effects of HPV, such as
lesion persistence and spontaneous regression, is played by
cellular immunity, particularly the T cell system. The fact that
immunosuppressed individuals (transplant, lymphoma, HIV
disease) have enhanced HPV proliferation and an increased
frequency of HPV infection and associated disease (Kast et al,
1996) illustrates the importance of cellular immunity. In
addition, reduced numbers of Langerhans cells are found in
CIN (Sherman et al, 1998), and dense in®ltrates of T
lymphocytes and macrophages are found in regressing warts.
In benign lesions viral DNA remains extrachromosomal. The
viral DNA is incorporated into the host chromosome in most
cervical cancers. Two of the viral genes, E6 and E7, are
consistently retained and expressed in cervical cancers. These
same HPV types show transforming activity (Schlegel et al,
1988) in cultured cells. Continued growth requires these
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transforming proteins that may also act as tumor rejection
antigens.
CLINICAL DISEASE
Most clinically apparent genital HPV infections are benign.
Subclinical genital infections with HPV are extremely common.
A spectrum of disease results from genital HPV infection ranging
from asymptomatic infection to invasive cervical cancer. Based on
their association with cervical cancer, HPV types have been divided
into low and high risks. External genital warts are the most
common clinical expression of infection with low-risk HPV
(Beutner et al, 1998a). The giant condyloma of Buschke-
Lowenstein caused by HPV type 6 (and sometimes HPV 11) is a
rare verrucous carcinoma of the external genital area. Weeks,
months, or years may be required from the time of HPV infection
to development of warts. Warts, once clinically apparent, may
persist, spread, grow, spontaneously regress, and/or recur. A rare
but devastating condition caused by perinatally acquired laryngeal
low-risk HPV infection is termed juvenile laryngeal papillomatosis
(JLP) and is usually due to infection with HPV 6 or 11.
The clinical manifestations of high-risk HPV types include
abnormal pap smears, low-grade squamous intraepithelial lesions
(LSIL), high-grade squamous intraepithelial lesions (HSIL), atypical
squamous cells of uncertain signi®cance (ASCUS), and atypical
glandular cells of uncertain signi®cance (AGUS) or, on biopsy,
cervical intraepithelial neoplasia, carcinoma in situ, and invasive
cervical cancer. Some anogenital cancers are strongly associated
with infection with certain HPV types. Almost all invasive cervical
cancers and cervical intraepithelial neoplasia (CIN) contain HPV
DNA. Weeks to decades may pass between infection to the
appearance of cervical dysplasia and cervical cancer. As the vast
majority of women infected with high-risk HPV never develop
cervical cancer, these HPV types are considered necessary but not
suf®cient for the development of cancer. Certain cofactors are
necessary but are currently not well understood. Thus, it is believed
that if the acquisition of HPV could be prevented, cervical cancer
could be greatly reduced, if not eliminated.
The clinical manifestations of the high-risk HPV types on the
external genital area are papular lesions (Bowenoid papulosis) or
erythematous scaly patches (Bowen's disease), which histologically
have been classi®ed as squamous cell carcinoma in situ or vulvar
intraepithelial neoplasia, or penile intraepithelial neoplasia; or, in
the vagina, as vaginal intraepithelial neoplasia. Rarely, invasive
squamous cell cancer of the penis, vulva, or vagina results.
The oncogenic potential of the high-risk HPV types is frequently
found in the anus as well as the cervix, because both structures
histologically have transformation zones where columnar epithe-
lium changes to strati®ed squamous epithelium. Anal HPV
infection has best been characterized in men, and its natural history
is the subject of ongoing studies.
EPIDEMIOLOGY/EXPECTED IMPACT OF AN
EFFECTIVE VACCINE
It has been estimated that 1% of sexually active persons in the
U.S.A. have visible genital warts (Koutsky et al, 1988). Because
HPV 6 and 11 cause the majority (>90%) of genital warts, it is
feasible to develop an effective bivalent vaccine for these low-risk
infections. Genital warts consume healthcare resources and are
emotionally troubling for the patients, although they are rarely
associated with signi®cant mortality or morbidity. Thus, immuni-
zation is an important goal. HPV infects about 50% of young
sexually active women (Bauer et al, 1991; Koutsky et al, 1992; Ho,
1998). The leading cause of cancer death in women under the age
of 50 worldwide is cervical cancer (Rowen and Lacey, 1998). In
countries where screening is unavailable or underused the impact of
HPV infection is greatest. Vaccination against HPV is an attractive
goal due to this strong association between sexually acquired HPV
and cervical cancer. The majority of cervical carcinomas is
associated with relatively few HPV types and animal models have
consistently shown that both prophylactic and therapeutic vaccin-
ation is feasible. The worldwide public health implication of both
preventive and therapeutic vaccines not only includes saving lives,
but also decreasing the cost of screening and treating premalignant
cervical disease. The annual cost of HPV-related disease has
recently been estimated by the Institute of Medicine to be $10
billion (Eng and Butler, 1996).
HISTORY/BACKGROUND OF VACCINE RESEARCH
AND OTHER STRATEGIES FOR CONTROL
The inability to culture HPV and host tropism of the virus has
hampered vaccine development. Cottontail rabbit papillomavirus
(CRPV) studies established over 60 y ago that antibodies elicited by
the injection of intact virions protect against experimental challenge
by the homologous viral type (Shope, 1935). Intact virions
displaying immunodominant epitopes were found to be needed
to induce protective antibodies (Shope, 1935; Kidd, 1938;
Pilacinski et al, 1986; Jin et al, 1990; Ghim et al, 1991). It was
demonstrated that the L1 major capsid protein of HPV expressed in
eukaryotic cells self-assembles into virus-like particles (VLP), which
resemble authentic virions without the viral genome and its
transforming genes. Neutralizing antibodies generated against
con®rmational epitopes found on the surface of native virions
and VLP are suf®cient to prevent infection both in vitro and in
animal models.
Immunotherapy is another strategy for HPV control. Cells
involved in the host defense can be collected from patients with
cervical cancer or a histocompatible donor and then grown and
activated ex vivo by cytokines such as recombinant IL-2 and
transferred back to the cancer patient as therapy in a process known
as adoptive cellular transfer (Hines et al, 1998). This approach
(Boursnell et al, 1996; Krul et al, 1996) provided some protection
against HPV 16 and 18 E6 and E7-positive tumors in mouse
models.
VACCINE STRATEGIES
Prophylactic vaccines Protective anti-HPV antibodies to
prevent infection are induced by HPV subunit vaccines.
Antigenic targets in most prophylactic vaccine studies consist of
L1 and L2. Fusion proteins, vaccinia virus recombinants, plasmids,
and VLP are used in preparation of these vaccines. Molecular
techniques (Rose et al, 1993) are used to produce VLP that are
spherical 50 nm structures resembling hollow viral capsids. These
VLP lack oncogenic DNA, but possess structurally intact viral
capsid proteins and may be used in enzyme-linked immunosorbent
and hemagglutination assays to detect humoral responses to HPV
(Sherman et al, 1998).
Therapeutic vaccines Therapeutic vaccination may be used to
eliminate residual cancer, cause regression of existing CIN or warts,
or prevent progression of infection or low-grade disease to higher-
risk lesions. Potential targets in the development of therapeutic
vaccines include HPV E6 and E7 epitope peptides selectively
maintained and expressed during malignant progression. Human
leukocyte antigen (HLA)-speci®c, human cytotoxic T lymphocytes
(CLT) induced against E6 and E7 peptides have been shown to
cause lysis of HLA-speci®c HPV-positive cervical carcinoma cell
lines (Feltkamp et al, 1993; Alexander et al, 1996) in in vitro studies.
ANIMAL MODELS
Because HPV is species-speci®c, it does not cause disease in
animals, so extrapolating data to humans must be done with
caution. Encouraging results have been obtained, however, using
species-speci®c PV. Experimental infection in vivo can be prevented
with immunization with proteins produced in bacteria or
immunization with vaccinia vectors that express L1 and/or L2,
although low levels of neutralizing antibodies are induced
(Pilacinski et al, 1986; Jarrett et al, 1991; Lin et al, 1992). On the
other hand, VLP vaccines are strongly immunogenic. Experimental
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infection with native virus speci®c to beagle dogs (COPV) (Bell et
al, 1994; Suzich et al, 1995), cottontail rabbits (CRPV) (Donnelly et
al, 1991; Lin et al, 1993; Breitburd et al, 1995; Christensen et al,
1996), and calves (BPV) (Kirnbauer et al, 1996) can be prevented by
prior immunization with homologous VLP. Both species and type
speci®c protection is produced by neutralizing antisera.
Con®rmational epitopes present on the surface of VLP also help
determine protection.
Systemic vaccination in animal models has produced protection
of mucosal surfaces against the natural transmission of PV. HPV-
11 L1 VLP-speci®c IgG present in the cervicovaginal secretions of
monkeys parenterally immunized with HPV-11 L1 VLP is suf®-
cient to neutralize HPV-11 in the athymic mouse xenograft system
(Lowe et al, 1997).
Therapeutic vaccines may target early antigens, including E1, E6,
and E7 proteins. Regression of tumors derived from HPV 16-
transformed oncogenic cell lines (Meneguzzi et al, 1991) have been
observed in rats vaccinated with vaccinia virus expressing HPV 16
E7. Prevention and regression of CRPV tumors were both
achieved using an E1 vaccine derived from recombinant Listeria
monocytogenes (Jensen et al, 1997). A mechanism to eliminate cells
undergoing productive viral infection is provided by T cell
responses induced by HPV-16 L1 VLP (Dupuy et al, 1997;
Luxton et al, 1997).
Studies with animal models have not evaluated authentic routes
of PV infection or the longevity of immune responses, or
established that tumors can be eliminated with vaccination, despite
these encouraging results.
CLINICAL STUDIES
Immunology and ef®cacy studies Currently numerous
clinical studies are underway throughout the world and a few
have obtained data as described below.
In a phase I study with 65 healthy volunteers a vaccine speci®c
for HPV type 11 was found to be both safe and immunogenic
(Reichman et al, 1998). The major capsid protein, L1, was placed in
a recombinant virus, expressed in insect cells, and VLP were
produced. Volunteers seronegative for HPV-11 were given vaccine
composed of 3, 9, 30, or 100 mg of VLP or placebo at 0, 4, and
16 wk. Neutralizing antibody titers against HPV 11 of 1:1000 or
greater were achieved in seven of 10 subjects who received the
3 mg dose, nine of 10 who received the 9 mg dose, all 12 who
received the 30 mg dose, and all 10 who received the 100 mg dose.
The vaccine was well tolerated at all doses.
No signi®cant toxicities, an antivaccine antibody response in all
eight participants, and HPV-speci®c antibody response in three of
eight participants resulted from a recombinant vaccine virus
expressing E6 and E7 epitope peptides of HPV 16 and 18 in a
phase I/II study in advanced cervical carcinoma (Borysiewiez et al,
1996).
Good humoral responses were produced in open-label studies
with an L2 E7 fusion protein vaccine, incorporating an alum
adjuvant combined with conventional therapy for the treatment of
anogenital warts in men, although lymphoproliferative responses
were variable (Lacey et al, 1997; Rowen et al, 1997).
Vaccine development A number of vaccines are in various
stages of development (Table I). There are a number of
observations that would seem to indicate that effective HPV
vaccination is feasible although modern pivotal ef®cacy trials with
HPV have not been completed. These observations are as follows:
1 more persistent and more frequent clinical expression of HPV
infection (which is usually more dif®cult to treat) results from
immunosuppression;
2 vaccine studies with animal papillomavirus systems have pro-
duced favorable results;
3 many infected humans never express their clinical lesions;
4 external genital warts, nongenital warts, and HPV-related
cervical lesions often regress spontaneously;
5 in®ltrates of regressing warts often contain CD4 lymphocytes
and macrophages;
6 autologous vaccines have been reported to be successful in
humans.
The possibility that a genital HPV vaccine might not be
effective, on the other hand, is suggested by the following factors
that make HPV vaccines particularly challenging:
1 There is no clear de®nition of protective immunity, nor is the
necessary response to particular antigens well understood.
Antibodies appear to protect against infection in animal systems,
and cell-mediated immune responses are required for wart
regression or protection against the development of warts.
2 With HPV the route and frequency with which the immunized
subject is exposed naturally may be more chronic and repetitive
than with other viral infections for which we have effective
vaccines. The level of immunity required to protect against
frequent genital exposure is unknown. Viral infections for which
we currently have vaccines are not characterized by frequent
(potentially daily) exposure for years.
Table I. Candidate HPV vaccines
Peptide vaccines
HLA-A0201 HPV-16 lipopeptides Steller and Schiller, 1996
HPV 16 E7 PADRE Feltkamp et al, 1993
HPV 16 E7 ``ISCAR'' conjugate Tindle et al, 1995
Protein-based vaccines
HPV 16 E6-E7 Mallarios et al, 1999
HPV 16 E7 + BCG H5/65 Zhu et al, 1995
HPV 16 E7 Hariharan et al, 1998
HPV 16 E2 Heinemann et al, 1999;
Hibma et al, 1999
HPV 16 E4 with HbeAg El Mehdaoui et al, 1999
Virus-like particles
HPV 11 L1 Reichman et al, 1999
HPV 6 L1 Zhang et al, 1999
HPV 16 L1 Da Silva et al, 1999
Viral vector vaccines
Vaccinia HPV 16 L1 Cooney et al, 1991;
Gao et al, 1994
Vaccinia HPV 16-E7 Lin et al et al 1993, 1996
Vaccinia HPV 16 + 18 E6 + E7 Borysiewicz et al, 1996
Bacterial vectors
Salmonella typhimurium HPV 16 E6
and E7
Krul et al, 1996;
London et al, 1996
Salmonella typhimurium HPV16 L1 Nardelli-Ha¯inger et al, 1997
Streptococcus gordovii HPV16 E7 Jensen et al, 1997
Table II. Potential clinical trial end-points
High-risk genital HPV
Prophylactic
Acquisition of infection
Shortening duration of infection
Decrease in frequency of cytologic abnormalities
Decrease in duration of cytologic abnormalities
Therapeutic
Resolution of cytologic abnormalities
Regression of dysplasia (monotherapy or combination therapies)
Regression of cancer (monotherapy or combination therapies)
Low-risk genital HPV
Prophylactic
Acquisition of infection
Development of warts
Therapeutic
Monotherapy or combination therapies
Prevention of recurrence after treatment
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Although both prophylactic and therapeutic vaccines are feasible
(Table II), prophylactic vaccines are the most appealing, based on
experience with animal PV and in humans, with a number of viral
vaccines in clinical trials.
A vaccine to control genital HPV probably would need to
involve immunization of both men and women. Our knowledge of
detection of high-risk HPV in women, the attack rate of HPV in
women, and the natural history of HPV in women, however, is
much greater than our information about infectivity, attack rate,
and natural history of HPV in men.
Development of vaccination strategy and rational design of
clinical trials is dif®cult without this information. The lack of a
readily available standardized and validated serologic test to
determine who is ``immune'' and who is susceptible is another
obstacle to HPV vaccine development and implementation. VLP
ELISA and pseudovirion infectivity assays serve as surrogate
markers. In addition, the detection of viral DNA and cervical
lesions will characterize patients at entry and serve as markers to
determine vaccine ef®cacy.
There are major psychosocial challenges in addition to the
scienti®c challenges. We do not know if the public is ready to
vaccinate their children for sexually transmitted diseases. In
addition, small but vocal groups question the value of current
childhood vaccinations. There is very little awareness of HPV
among the general public, and the risk of acquiring HPV and the
reality that cervical cancer is a sexually transmitted disease are
unfamiliar concepts outside the medical community.
POTENTIAL VACCINES
Peptide vaccines Peptide vaccines have obvious therapeutic
appeal, particularly if capable of binding to HLA and generating
cytotoxic T lymphocytes. Peptide vaccines are in early trials as
candidate therapeutic vaccines for cervical cancer.
Proteins Production of fusion proteins of all HPV gene
products is now possible, but which of these or which
combinations should be studied in clinical trials is not known. An
HPV6 L2-E7 fusion protein has been shown to be immunogenic,
and perhaps therapeutic, in the treatment of genital warts in
humans.
Virus-like particles Chimeric VLP can be formed by
combining L1 or L1 plus L2 with early proteins. Clinical trials
are being conducted with an HPV 11 VLP (Reichman et al, 1998,
1999), an HPV6 L1 VLP (Zhang et al, 1999), and an HPV 16 L1
VLP (Da Silva et al, 1999).
Viral and bacterial vectors Viral and bacterial vector vaccines
are potentially equivalent to live attenuated HPV vaccines.
Humoral and CTL responses could potentially be generated with
such vaccines, which could be polyvalent. Early clinical trials in
human cervical cancer patients are evaluating viral vector vaccines
such as a vaccinia vaccine expressing modi®ed forms of E6 and E7
from HPV 16 and 18 (Borysiewicz et al, 1996), which appear to be
immunogenic.
Other approaches It is theoretically possible to elicit virus-
speci®c immune responses utilizing direct introduction into the
host of viral DNA coding for viral antigens. This approach has only
been investigated in the rabbit system thus far.
Low-risk types The goal of vaccination with low-risk types is
primary prevention of HPV acquisition. If this goal cannot be
achieved, it is hoped that vaccination can at least prevent the
development of external genital warts. There is a lack of precise
knowledge about infectivity, susceptibility, attack rate, and time
from infection to the development of external genital warts.
Although the presence or absence of such lesions would represent a
clear clinical end-point, designing clinical trials in terms of sample
size and duration of follow-up is challenging without this
information.
Therapeutic end-points could be achieved with a low-risk HPV
vaccine, either by accelerating the resolution of genital warts,
enhancing the ef®cacy of current therapies, or preventing wart
recurrence after current therapy has produced a wart-free state. The
precise frequency and factors that favor or prevent ``spontaneous''
resolution of genital warts are poorly understood. Complete
resolution of genital warts over a few months appears to be in
the range of 0%±20% based on the placebo arm of controlled
clinical trials (Beutner et al, 1998b).
Most current therapies have about a 50% complete response rate.
Increasing complete responses from 50% to 80% by supplementing
current treatment with a vaccine would require a trial using
hundreds of patients.
If one hopes to decrease recurrences after conventional therapy,
similar challenges exist. There have been no studies prospectively
powered and designed to establish the frequency of or time to
recurrence following treatment of genital warts with any modality,
although published recurrence rates with most modalities appear to
be high. In order to design vaccine trials adequately, this
information will be required.
High-risk HPV types Prevention of cervical cancer is the
obvious aim of vaccination against high-risk HPV types, but it is
not a practical end-point for human vaccine trials. Because the
biopsy may alter the natural history, histologic end-points are not
feasible. Several potential surrogate end-points are of potential use:
the acquisition of infection, the virologic persistence, and a decrease
in the proportion of subjects who experience cytologic
abnormalities.
In theory the best way to prevent cervical cancer is to prevent
the acquisition of high-risk HPV infection, but this may also be the
greatest challenge. The lack of a serologic test to accurately identify
those who are either susceptible or immune is one of the many
problems with this end-point. While virgins would be susceptible,
limiting enrolment to virgins has some logistic limitations.
The persistence of HPV, not just the acquisition of a short-lived
infection, is a critical step in the pathway to cancer, which may help
explain why only a minority of those infected develop cervical
cancer. Cervical cancer may thereby potentially be prevented using
a vaccine to decrease the proportion of the population with
persistent HPV. Inherent limitations in terms of interpretation and
reproducibility exists with the use of a screening cytologic test as a
clinical end-point.
CONCLUSION
We have come a long way on the path to a vaccine considering that
HPV cannot be grown in vitro and that until very recently there
have been no serologic tests for HPV. Although large-scale clinical
trials are now underway, it is dif®cult to predict how soon we will
have effective prophylactic and/or therapeutic HPV vaccines.
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